Breaking News

Flawed Paxil study came with cautionary note — if you knew how to find it 

April 15, 2026
Pharmalot Columnist, Senior Writer
Adobe

STAT+ | Flawed study on the antidepressant Paxil came with a cautionary note — if you knew how to find it

Study on the antidepressant Paxil now carries an 'expression of concern' that it's under review for possible retraction. The notice is not easy to find.

By Ed Silverman


STAT+ | FDA panel will meet to discuss allowing broader access to certain peptides

Legal peptides draw closer: Kennedy schedules FDA advisory meeting for July, and he gets to appoint the experts who will consider reversing a Biden-era ban.

By Lizzy Lawrence and Sarah Todd


STAT+ | New Bain biotech startup, building on BMS drugs, gets a name and a CEO

Last summer, Bain Capital Life Sciences said it would form the startup, created with $300 million and five drugs licensed from Bristol Myers Squibb.

By Allison DeAngelis



More around STAT
Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

Enjoying Pharmalot? Tell us about your experience
Continue reading the latest health & science news with the STAT app
Download on the App Store or get it on Google Play
STAT
STAT, 1 Exchange Place, Boston, MA
©2026, All Rights Reserved.

No comments